Quoin Pharmaceuticals, Inc.

Contributing Author

Recent Articles by Quoin Pharmaceuticals, Inc.

May-22	Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study QNRX GlobeNewswire
May-20	Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome QNRX GlobeNewswire
May-14	Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study QNRX GlobeNewswire
May-13	Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial Results QNRX GlobeNewswire
May-06	Quoin Pharmaceuticals to Announce First Quarter 2025 Financial Results on Tuesday, May 13, 2025 QNRX GlobeNewswire